Biocytogen 

Animal Models and Cell Lines

>Single Humanized Immune-Checkpoint Mice
B-hCD137(4-1BB) mice
This co-stimulatory signal can also multiply antigen presenting cells and result in cell factor secretion. Experiments show that CD137 co-stimulation regulates T cell and antigen presenting cell function for antitumor immunity, providing new targets for tumor immunological therapies.
B-hBTLA mice
BTLA binds to its ligand HVEM (HVEM is a member of the tumor necrosis factor receptor superfamily) to transmit a co-inhibition signal in the body's anti-tumor immune response, and is associated with the immune escape mechanism of the tumor.
B-hCD27 mice
Treating mice with a CD27 agonist antibody effectively enhanced the antitumor immune response for lymphoma and B16 melanoma, providing putative targets for tumor immunotherapy.
B-hCD28 mice
CD28 is the only B7 receptor constitutively expressed on naïve T cells. Association of the TCR of a naive T cell with MHC: antigen complex without CD28:B7 interaction results in a T cell that is anergic. Agonistic antibodies targeting CD28 have entered clinical trials.
B-hCD40 mice
CD40 (cluster of differentiation 40) is a tumor necrosis factor receptor superfamily member expressed on APC such as dendritic cells (DC), B cells, and monocytes as well as many non-immune cells and a wide range of tumors.
B-hCD47 (B/c) mice
CD47 is an important “self ” mark on the cell surface and inhibits macrophagocytosis by interaction with SIRPα on macrophage surface. Animal studies have shown that a CD47 antibody is an effective treatment for multiple types of tumors. CD47 is another target for tumor immunity following PD-1/PD-L1.

© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud
in the section of your HTML pages